BrainsWay (BWAY)

Generated: April 19, 2026

Red Dot

Statistics

Metric	Value
Last Close	$15.33
Blended Price Target	12.43
Blended Margin of Safety	-18.9% Overvalued
Rule of 40 (Next)	43.1%
Rule of 40 (Current)	47.3%
FCF-ROIC	20.3%
Sales Growth Next Year	22.7%
Sales Growth Current Year	27.0%
Sales 3-Year Avg	26.4%
Industry	Medical Devices

Analysis

BrainsWay has evolved from a pre-commercial research company into a profitable, high-growth medical device manufacturer with genuine competitive defensibility. The company achieved 10 consecutive quarters of profitability through 2025, demonstrating that its business model has matured beyond the typical cash-burn phase of early-stage medtech firms. Revenue growth of 27% annually, combined with expanding gross margins and a strategic shift toward recurring lease revenue, suggests the business is entering a more durable phase where growth is increasingly supported by predictable, multi-year customer contracts rather than one-time system sales.

The durability of this growth depends critically on three factors working in concert: regulatory exclusivity in high-value indications like OCD, which creates a pricing moat; expanding reimbursement coverage that removes adoption friction; and a growing installed base of 1,700 systems generating recurring service and lease revenue. The company's remaining performance obligations of approximately $70 million provide substantial revenue visibility. Management has guided for 27–30% revenue growth in 2026, suggesting confidence in sustained momentum, though this growth rate will eventually moderate as the company scales.

The primary vulnerability is execution risk in expanding beyond OCD into adjacent indications and maintaining insurance reimbursement as a non-invasive alternative to pharmaceuticals and invasive procedures. The company's ability to defend its moat depends on continued clinical evidence generation and R&D investment. Overall, BrainsWay presents a business with legitimate competitive advantages, predictable revenue streams, and a clear path to sustained profitability—characteristics that distinguish it from typical high-growth medtech startups.

What the Company Does

BrainsWay designs, manufactures, and distributes Deep Transcranial Magnetic Stimulation (Deep TMS) systems, a non-invasive neuromodulation platform used to treat brain disorders including obsessive-compulsive disorder, depression, and other neuropsychiatric conditions. The company sells or leases these systems to psychiatrists, hospitals, and specialized mental health clinics. Each system costs approximately $100,000, and the company has built a 1,700-unit installed base as of Q4 2025.

The company generates revenue through two primary channels: system sales and recurring lease arrangements. As of early 2024, lease revenues accounted for over 58% of total revenue, a significant shift from the company's earlier direct-sales model.^[2] This recurring revenue stream is supplemented by service contracts, consumables, and training fees associated with the installed base. The transition to leasing has accelerated customer adoption by reducing upfront capital barriers for clinics.

Revenue Recurrence & Predictability

Approximately 58% of BrainsWay's revenue is recurring, derived from multi-year lease agreements and service contracts on its installed base.^[2] These leases typically span multiple years and generate predictable monthly or quarterly cash flows. The company reports customer retention of 93%, indicating strong stickiness once a clinic adopts Deep TMS.^[5] Remaining performance obligations of $70 million as of Q4 2025 provide substantial forward revenue visibility, representing contracted revenue expected to be recognized over future periods.

The remaining 42% of revenue comes from system sales, which are more transactional in nature but benefit from the company's growing market presence and expanding reimbursement coverage. The shift toward leasing has materially improved revenue predictability and reduced the lumpiness associated with large one-time sales. This structural change, combined with high customer retention and multi-year contracts, positions BrainsWay well on the recurrence dimension—a quality that typically commands premium valuations in medtech.

Revenue Growth Durability

BrainsWay's 27% full-year 2025 revenue growth was driven by three primary levers: increased system shipments (up 27% in Q4 2025), expanding reimbursement coverage, and growing adoption among both new and existing customers.^[1] The company's total addressable market in neuromodulation for psychiatric and neurological disorders remains large and underpenetrated. With only 1,700 systems installed globally, significant whitespace exists for geographic expansion and penetration of existing markets.

The primary structural tailwind is expanding insurance reimbursement, which removes a critical adoption barrier for clinics and patients. The company is also pursuing new therapeutic indications beyond OCD, which could unlock adjacent markets. However, growth will eventually decelerate as the company scales and market saturation increases in core geographies. Competitive entry from larger medtech firms or alternative neuromodulation technologies represents a longer-term headwind, though BrainsWay's regulatory exclusivity in OCD provides near-term protection.

Economic Moat

BrainsWay's moat is exceptionally strong and multifaceted. The company holds exclusive FDA approval for Deep TMS in treating OCD, creating a regulatory moat that prevents direct device competition in this high-value indication.^[2] For clinics seeking an FDA-cleared OCD treatment, BrainsWay is the only option, allowing the company to function as a price-setter. This exclusivity is reinforced by a robust patent portfolio protecting its proprietary H-coil technology.

The moat is further strengthened by an extensive library of over 110 peer-reviewed articles supporting Deep TMS efficacy, which provides physicians with clinical justification for adoption.^[2] The company's significant R&D spending—approximately 22% of revenue—supports continued clinical evidence generation and defense of its technological leadership. The shift toward recurring lease revenue creates switching costs, as clinics become operationally dependent on the Deep TMS platform. However, the moat is not impenetrable; it depends on sustained reimbursement and clinical evidence, and larger competitors could eventually challenge the company through alternative technologies or indications.

Management & Leadership

Hadar Levy serves as Chief Executive Officer and has led the company through its transition from pre-commercial to profitable growth stage. Levy's strategic pivot toward recurring lease revenue and focus on expanding reimbursement coverage have materially improved the company's financial profile. The company achieved 10 consecutive quarters of profitability under his leadership, demonstrating disciplined capital allocation and operational execution.

Insider ownership levels and specific capital allocation decisions are not detailed in available recent sources. However, the company's consistent guidance and achievement of profitability targets suggest management credibility with investors and stakeholders. The CEO's public statements emphasize long-term market expansion and clinical evidence generation rather than short-term financial engineering, which aligns with the company's strategic positioning.

Key Risks

Reimbursement Dependency: BrainsWay's growth is heavily dependent on insurance reimbursement coverage expansion. If payers restrict coverage or impose unfavorable reimbursement rates, adoption could slow materially. The company has limited control over reimbursement decisions, which are made by third parties and subject to changing healthcare policy.

Regulatory and Clinical Risk: Maintaining FDA exclusivity in OCD requires sustained clinical evidence and regulatory compliance. Adverse clinical outcomes, manufacturing issues, or competitive regulatory approvals could erode the company's moat. The company must continue investing in R&D and clinical studies to defend its position and expand into new indications.

Competitive Threat: Larger medtech companies with greater resources could enter the neuromodulation market or develop alternative technologies. Pharmaceutical competitors offering novel psychiatric treatments could also reduce demand for Deep TMS. The company's small scale relative to competitors like Medtronic or Boston Scientific creates execution risk if competitive intensity increases.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks: 77 Quality Growth Stocks — Week of April 19, 2026 April 19, 2026